Clinical Trial Update: Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing effectiveness and safety of Dysport for hemifacial spasm has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemifacial Spasm

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Hemifacial Spasm | Phase 3 | Status: COMPLETED